We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Corbus Pharmaceuticals (CRBP) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Corbus Pharmaceuticals (CRBP - Free Report) closed the most recent trading day at $7.18, moving -0.97% from the previous trading session. This move lagged the S&P 500's daily gain of 0.72%. Meanwhile, the Dow gained 0.55%, and the Nasdaq, a tech-heavy index, added 0.71%.
Prior to today's trading, shares of the drug developer had lost 15.8% over the past month. This has lagged the Medical sector's loss of 0.66% and the S&P 500's gain of 0.28% in that time.
CRBP will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0, up 100% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $18.96 million, up 1895.79% from the prior-year quarter.
CRBP's full-year Zacks Consensus Estimates are calling for earnings of -$0.85 per share and revenue of $22.18 million. These results would represent year-over-year changes of +13.27% and +359.89%, respectively.
It is also important to note the recent changes to analyst estimates for CRBP. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 6.12% higher. CRBP is currently a Zacks Rank #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 70, putting it in the top 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRBP in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Corbus Pharmaceuticals (CRBP) Stock Sinks As Market Gains: What You Should Know
Corbus Pharmaceuticals (CRBP - Free Report) closed the most recent trading day at $7.18, moving -0.97% from the previous trading session. This move lagged the S&P 500's daily gain of 0.72%. Meanwhile, the Dow gained 0.55%, and the Nasdaq, a tech-heavy index, added 0.71%.
Prior to today's trading, shares of the drug developer had lost 15.8% over the past month. This has lagged the Medical sector's loss of 0.66% and the S&P 500's gain of 0.28% in that time.
CRBP will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0, up 100% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $18.96 million, up 1895.79% from the prior-year quarter.
CRBP's full-year Zacks Consensus Estimates are calling for earnings of -$0.85 per share and revenue of $22.18 million. These results would represent year-over-year changes of +13.27% and +359.89%, respectively.
It is also important to note the recent changes to analyst estimates for CRBP. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 6.12% higher. CRBP is currently a Zacks Rank #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 70, putting it in the top 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRBP in the coming trading sessions, be sure to utilize Zacks.com.